论文部分内容阅读
目的探讨血小板计数与晚期非小细胞肺癌之间的关系及其临床意义。方法对147例病理及临床确诊晚期非小细胞肺癌患者在首治前采集空腹外周血1.5 ml进行周围血小板计数检查,排除药物及疾病的影响,血小板高于300×109/L为增多,所有病例均接受GP或NP方案化疗4周期,以30例同期保健科体检的健康人作为对照组。结果血小板增多发生率为48.3%,与肺癌病理学类型无关,与对照组相比差异有统计学意义。晚期非小细胞肺癌组血小板计数平均值为(358.76±146.52)×109/L明显高于对照组(204.57±52.18)×109/L。肺癌患者中,血小板增多组化疗有效率为43.7%,显著低于血小板正常组62.1%。结论血小板计数可作为晚期非小细胞肺癌辅助诊断和评估预后的一个指标。在晚期肺癌综合治疗中,要注意抗血小板治疗。
Objective To investigate the relationship between platelet count and advanced non-small cell lung cancer and its clinical significance. Methods 147 cases of pathologically and clinically diagnosed advanced non-small cell lung cancer patients before the first collection of fasting peripheral blood of 1.5 ml peripheral platelet count examination to exclude the impact of drugs and diseases, platelets higher than 300 × 109 / L was increased in all cases All patients underwent GP or NP regimen for 4 cycles, and healthy subjects of 30 cases during the same period were selected as control group. Results The incidence of thrombocytosis was 48.3%, which was not related to the pathological type of lung cancer. The difference was statistically significant compared with the control group. The average platelet count in advanced non-small cell lung cancer group was (358.76 ± 146.52) × 109 / L, which was significantly higher than that in control group (204.57 ± 52.18) × 109 / L. Lung cancer patients, thrombocytosis chemotherapy was 43.7%, significantly lower than the platelet normal group 62.1%. Conclusion Platelet count can be used as a prognostic indicator in advanced non-small cell lung cancer. In advanced lung cancer comprehensive treatment, pay attention to antiplatelet therapy.